BioMarin Pharma (BMRN) Misses Q1 EPS by 7c; Raises FY12 Sales Guidance
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q1 EPS of ($0.21), $0.07 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $116.6 million versus the consensus estimate of $119.24 million.
Sees FY2012 revenue of $475-$510 million, versus prior guidance of $465-$510 million and the consensus of $487.87 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Sees FY2012 revenue of $475-$510 million, versus prior guidance of $465-$510 million and the consensus of $487.87 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.